Objective-SCUBE2 (signal peptide-CUB-EGF domain-containing protein 2), expressed on the endothelial cell surface, functions as a novel coreceptor for VEGFR2 (vascular endothelial growth factor receptor 2) and enhances VEGF-induced signaling in adult angiogenesis. However, whether SCUBE2 plays a role in pathological angiogenesis and whether anti-SCUBE2 antibody is an effective strategy for blocking tumor angiogenesis remain unknown. The aim of this study was to investigate the pathological role and targeting therapy of SCUBE2 in tumor vasculature. Approach and Results-Immunohistochemistry revealed that SCUBE2 is highly expressed in endothelial cells of numerous carcinomas. Genetic endothelial cell knockout of SCUBE2 and pharmacological inhibition with the anti-SCUBE2 monoclonal antibody SP.B1 significantly reduced xenograft tumor growth, decreased tumor vascular density, increased apoptosis, and decreased the proliferation of tumor cells. Mechanistic studies revealed that SP.B1 binds to SCUBE2 and induces its internalization for lysosomal degradation, thereby reducing its cell surface level and inhibiting the binding of and downstream signaling of VEGF, including VEGFR2 phosphorylation and AKT/MAPK (mitogen-activated protein kinase) activation. Importantly, dual combination therapy with anti-SCUBE2 monoclonal antibody and anti-VEGF antibody or chemotherapy was more effective than single-agent therapy. Conclusions-Endothelial cell surface SCUBE2 is a VEGFR2 coreceptor essential for pathological tumor angiogenesis, and anti-SCUBE2 monoclonal antibody acting as an internalization inducer may provide a potent combination therapy for tumor angiogenesis. Visual Overview-An online visual overview is available for this article.
A ngiogenesis, the process of new blood vessel formation from preexisting vasculature, is a critical component of tumor progression. 1 Tumor growth relies on the development of new vasculature to provide nutrients and oxygen to the proliferating cancer cells while removing waste products and CO 2 .
1 VEGF (vascular endothelial growth factor) activates endothelial cells (ECs) via VEGFR2 (VEGF receptor 2; a receptor tyrosine kinase) to trigger downstream signaling including phosphatidylinositol 3-kinase/AKT and phospholipase C γ/MAPK (mitogen-activated protein kinase) cascades that together support EC proliferation, migration, and tube formation. 2, 3 These VEGF responses can be further facilitated by VEGFR2 coreceptors such as neuropilins, CD44, and CD146. [4] [5] [6] [7] Targeting VEGF/VEGFR2 pathways has become a prominent antiangiogenic strategy to complement chemotherapeutic approaches to treat cancer. 8 For example, bevacizumab, a specific anti-VEGF humanized monoclonal antibody (mAb), has been approved for treating metastatic colorectal cancer, renal cell carcinoma, and non-small cell lung cancer. [9] [10] [11] However, anti-VEGF targeting is often insufficient to control tumor growth because of intrinsic refractoriness or acquired resistance to bevacizumab. 12, 13 Therefore, the development of novel or adjunct therapies would be of great benefit to patients. Recently, VEGFR2 coreceptors (ie, CD146 and neuropilins) have emerged as attractive targets because blocking their functions by mAbs can enhance the ability of anti-VEGF antibody to suppress tumor growth or metastasis. 7, 14, 15 SCUBE2 (signal peptide-CUB-EGF domain-containing protein 2) is the second member of a relatively small gene family consisting of 3 genes (SCUBE1, 2, and 3) identified from human ECs. [16] [17] [18] [19] [20] [21] [22] Their gene products are ≈1000 amino acid polypeptides organized in a modular fashion with an NH 2 -terminal signal sequence, 9 copies of EGF-like repeats, a spacer region, 3 cysteine-rich motifs, and 1 CUB domain at the COOH terminus. [16] [17] [18] Our studies showed that SCUBE proteins can tether on the cell surface as peripheral membrane proteins via the spacer region and the cysteine-rich motifs by 2 independent membrane-associating mechanisms, electrostatic and lectin-glycan interactions, 23 to function as a coreceptor for many growth factors. [24] [25] [26] [27] [28] For instance, we recently demonstrated that hypoxia-inducible SCUBE2 interacted with VEGFR2 in ECs, where it behaves as a coreceptor for VEGFR2 to facilitate VEGF binding and promote its signal activity, including VEGFR2 phosphorylation and AKT or MAPK activation. The process enhances VEGF-induced angiogenesis. 28 We also found that ECs isolated from EC-specific Scube2-knockout (EC-KO) mice were impaired in their ability to sprout, proliferate, and form tubes in response to VEGF treatment. 28 Consistently, VEGF-induced VEGFR2 phosphorylation and AKT or MAPK activation were significantly inhibited in these Scube2-deficient ECs. 28 Furthermore, EC-KO mice showed impaired VEGFinduced neovascularization in implanted Matrigel plugs and compromised recovery of blood flow after hind limb ischemia. 28 However, whether endothelial SCUBE2 is involved in pathological tumor angiogenesis and whether anti-SCUBE2 antibody is a viable strategy for blocking tumor-related angiogenesis remain largely unknown and uninvestigated.
In this study, we first showed that SCUBE2 was highly expressed in tumor ECs. In EC-KO mice, xenograft tumor growth and tumor angiogenesis were markedly reduced. Moreover, we developed a function-blocking mAb (SP.B1) for SCUBE2 as an internalization inducer for cell surface SCUBE2 that inhibited VEGF-induced downstream signaling, including VEGFR2 phosphorylation, AKT, and MAPK activation in ECs. Most importantly, our animal experiments demonstrated that SP.B1 combined with anti-VEGF antibody (bevacizumab) or cytotoxic chemotherapeutic agents (docetaxel or gemcitabine) had an additive antitumor effect, with concomitant decreased tumor vessel density in numerous xenograft tumor models. Our findings reveal that SCUBE2 plays an important role in pathological tumor angiogenesis and also may be a novel target for combination therapy for tumor angiogenesis.
Materials and Methods

Antibodies and Reagents
Anti-SCUBE2 (catalog GX85173) polyclonal antibody was from GeneTex (Irvine, CA). Anti-phospho-VEGFR2 (Thr1059; catalog 3817), anti-phospho-MAPK p44/p42 (Thr202/Tyr204; catalog 9106), anti-MAPK p44/p42 (catalog 9102), anti-phospho-AKT (Ser473; catalog 9271), and anti-AKT (catalog 9272) antibodies were from Cell Signaling Technology (Danvers, MA). Anti-VEGFR2 antibody was from Thermo Scientific (Rockford, IL; catalog MA5-15157). Anti-VEGF (catalog sc-152), anti-EEA1 (early endosome antigen 1; catalog sc-137130), and anti-LAMP2 (lysosome-associated membrane protein 2; catalog sc-18822) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-CD31 (catalog ab28364) and anti-neuropilin-1 (catalog ab81321) antibodies were from Abcam (Cambridge, MA). Anti-Ki67 antibody was from DAKOCytomation (Glostrup, Denmark; catalog M7249). Recombinant VEGF 165 protein was from R&D Systems (Minneapolis, MN; catalog 293-VE).
Generation of Conditional
Scube2
Flox/Flox and EC-KO Mice
The conditional Scube2 Flox allele containing 2 loxP sites separated by 65 kb of genomic sequence covering exons 2 to 21 was produced as described. 28 To generate endothelial-specific conditional knockout mice, transgenic mice expressing Cre recombinase under the control of the Tie2 promoter 29 Flox/− (EC-KO) mice. To avoid the effect of the estrous cycle on pharmacological responses, male mice (except melanoma tumor model) were mainly used for all phenotyping comparisons of genotypes (n=5 or more as specified). All animal experiments were approved by the Institute Animal Care and Utilization Committee, Academia Sinica.
Production of a Functional Blocking mAb (SP.B1) Specific for SCUBE2
Splenocytes from BALB/c mice immunized with purified recombinant His-tagged SCUBE2-spacer region (residues 445-667) produced from HEK-293T cells were fused with myeloma cells to produce hybridomas. Hybridomas positive for SCUBE2 but not His-tag identified by ELISA were further cloned as described. 19, 30 Three independent clones (SP.A1, B1, and B2) were obtained. These mAb could specifically detected the recombinant full-length SCUBE2 protein expressed in HEK-293T cells but not SCUBE1 and SCUBE3 by Western blotting and flow cytometric analyses, respectively. Ascites fluids were prepared, and purified IgG was obtained using protein G chromatography. On the basis of its higher potency on blocking vessel tumor formation in vitro, the mAb SP.B1 was used throughout in this study to evaluate its therapeutic effects on various tumor models.
Tumor Xenografts in Mice
Xenograft tumors were generated by injecting 1×10 6 melanoma cells (B16F10), Lewis lung carcinoma (LLC) cells, or testis mouse Leydig tumor cells (MLTC-1) subcutaneously on flanks of control and EC-KO mice. After tumor growth for 16 days, the mice were euthanized using cervical dislocation and the tumors were fixed and embedded in paraffin for tissue sectioning. For the therapeutic tumor xenografts, 1×10 6 pancreatic carcinoma cells (PANC-1), colorectal carcinoma cells (LS 174T), or LLC were injected subcutaneously into the flanks of 8-week-old BALB/c nude mice. When pancreatic, colorectal, and lung tumors were ≈50 mm 3 , mice were randomized and received intraperitoneal injections of anti-SCUBE2 SP.B1 mAb (200 μg/mice), the anti-VEGF antibody bevacizumab (Avastin; 100 μg/mice), chemotherapy agents gemcitabine (100 mg/kg) or docetaxel (5 mg/kg), or their combination weekly. Tumor size was measured twice a week by using digital 
Orthotopic Pancreatic Tumor Model
PANC-1 cells were used to establish an orthotopic model of pancreatic tumor, as previously described. 31 In brief, cells (4×10 5 per mouse in a volume of 20 μL) were injected orthotopically into the pancreata of nude mice as follows: 5 mice in each group were anesthetized using anesthetic agents (1 μg/kg atropine sulfate, 50 μg/ kg ketamine, 11.66 μg/kg 2-(2.6-xylidino)-5.6-dihydro-4H-1.3-thiazine-hydrochloride, 0.5 μg/kg methylparaben); a small left abdominal flank incision was made; and tumor cells were injected into the subcapsular region of the pancreas using a 29-gauge needle. A cotton swab was held cautiously for 1 minute over the site of injection to prevent leakage. The peritoneum and skin incision were closed sequentially with absorbable suture. After 5 weeks, tumors were fluorescence imaged using an IVIS imaging system coupled to a data acquisition computer running living image software. Mice were then euthanized using cervical dislocation, and tumors were harvested and analyzed. All animal experiments were approved by the Institute Animal Care and Utilization Committee, Academia Sinica.
Immunohistochemistry
Tissue sections (5 μm thick) were dewaxed with xylene, rehydrated in graded concentrations of alcohol, treated with 3% H 2 O 2 for 20 minutes, washed with PBS, blocked with blocking solution (PBST supplemented with 2% BSA and 2% normal goat serum) for 1 hour, and incubated at room temperature overnight with anti-SCUBE2 antibody (5 μg/mL), anti-CD31 antibody (1 μg/mL), or anti-Ki67 antibody (1 μg/mL). Antibody binding was detected by using horseradish peroxidase-conjugated antibody and stable 3,3′-diaminobenzidine or 3-amino-9-ethylcarbazole peroxidase substrate. Hematoxylin was used for counterstaining.
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EC Proliferation Assay
The effect of SCUBE2 on proliferation of ECs was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described. 20 In brief, ECs were trypsinized and plated onto 96-well culture plates at 2000 cells per well in 100 µL complete media. The next day, cells were stimulated with VEGF (100 ng/mL) or control media for 4 days and cell numbers were tracked by MTT assay as the manufacturer instructed.
EC Tubulogenesis Assay
ECs (3×10 3 cells per well) were seeded on Matrigel (BD Biosciences) in 15-well µ-Slide angiogenesis plates (ibidi GmbH, München, Germany) with or without VEGF (100 ng/mL) for 18 hours at 37°C. Tubulogenesis was determined by counting vessels in 3 random fields per well.
Cell Surface Biotinylation Analysis
Cell surface biotinylation assays were performed as described. 32 In brief, human umbilical vein ECs were incubated with 0.5 mg/mL EZ-link Sulfo-NHS-SS-Biotin (Pierce, Rockford, IL) in PBS on ice. After 30 minutes, cells were washed 3× with ice-cold PBS and lysed in lysis buffer (50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA, 5 mmol/L sodium orthovanadate, 1% NP-40, and protease inhibitor cocktail). Biotinylated protein was pulled down by incubating with streptavidin-agarose beads (Pierce) at 4°C for 2 hours. The beads were washed 3× with lysis buffer and examined by Western blot analysis.
Confocal Immunofluorescence Microscopy
ECs were fixed in 4% formaldehyde, blocked with 2% FBS for 1 hour, and incubated with anti-SCUBE2 antibody (10 μg/mL), anti-EEA1 antibody (1 μg/mL), or anti-LAMP2 antibody (2 μg/mL) for 1 hour. Slides were washed 3× with PBS and stained with Alexa Fluor 488-labeled anti-chicken IgG antibody for 1 hour, then washed 3× in PBS and mounted by using VECTASHIELD mounting medium with DAPI (Vector Laboratories, Burlingame, CA). Fluorescence images were captured at room temperature under a confocal microscope (model LSM 510; Carl Zeiss, Thornwood, NY).
Flow Cytometry
Flow cytometry was used to measure EC surface SCUBE2, VEGFR2, or neuropilin-1 expression as we previously reported. 28 Antibodies and dilutions used against these molecules were as follows: SCUBE2 (10 μg/mL), VEGFR2 (5 μg/mL), or neuropilin-1 (5 μg/mL). Cultured human umbilical vein ECs were harvested and washed in fluorescenceactivated cell sorting (FACS) buffer (PBS+1% FBS). An aliquot of 5×10 5 cells was used for flow cytometry. All cells were preincubated on ice for 30 minutes with FACS buffer to block nonspecific binding. The abovementioned diluted antibodies were then added to cells for incubation on ice for 60 minutes. The cells were washed twice with 1 mL FACS buffer and resuspended in 500 μL FACS buffer. Immunofluorescence-stained samples were analyzed on an FACS Calibur flow cytometer (Becton Dickinson). Data analysis involved using CELL Quest.
RNA Extraction, cDNA Synthesis, and qPCR
Experiments were performed as described. 21, 22 Total RNA was prepared from cultured cells by the TRIzol method (Life Technologies, Grand Island, NY). First-strand cDNA synthesis with SuperScript II reverse transcriptase (Life Technologies, Grand Island, NY) involved 5 μg RNA. qPCR was performed with SYBR green detection reagent (Bio-Rad, Hercules, CA) with the TOptical Thermocycler fast realtime PCR system (Biometra, Göttingen, Germany). Each reaction contained 1 μL cDNA template. All samples were processed in triplicate with the thermal cycling profile 95°C for 5 minutes, 40 cycles of 35 s at 95°C and 60°C for 1 minute, followed by a dissociation curve program. Primer specificity was confirmed by the dissociation curve, which contained only a single peak. Primer sequences for PCR (5′-3′) were for human SCUBE2, forward, CAG GCA GAG TCC TGT GGA GT; reverse, TAA AAT GCA GCG TTC TCG TG; mouse SCUBE2, forward, CGT TTG GAC ACA AAA TGC AG; reverse, GGG ACA GGG TCA TGA AGA AA; human GAPDH, forward, TGA AGG TCG GAG TCA ACG G; reverse, AGA GTT AAA AGC AGC CCT GGT G; and mouse GAPDH, forward, GGC AAA TTC AAC GGC ACA GT; reverse, AAG ATG GTG ATG GGC TTC CC. The PCR amplification efficiencies and the threshold cycle value of each gene were determined by the instrument's software. 
Immunoprecipitation and Western Blot Analysis
Cells were washed once with PBS and lysed for 15 minutes on ice in lysis buffer. Lysates were clarified by centrifugation at 10 000g for 15 minutes at 4°C. Samples underwent immunoprecipitation and Western blot analysis as described.
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Statistical Analysis
Data are presented as mean±SD and were analyzed by Student t test (for 2 groups) or 1-way ANOVA (for ≥3 groups) with Tukey multiple comparison analysis using Prism 7 (GraphPad Software, La Jolla, CA). P<0.05 was considered statistically significant. 
Results
SCUBE2 Is Highly Expressed in Human Carcinoma ECs
Because SCUBE2 mRNA and protein but not SCUBE1 or 3 were specifically induced by HIF-1α (hypoxia-inducible factor 1α) in human ECs cultured under hypoxic conditions 28 and because many cancers contain areas of intratumoral hypoxia, 33 we used immunohistochemistry to examine whether the SCUBE2 protein was upregulated in tumor ECs in vivo. Immunohistochemistry revealed that SCUBE2 was indeed highly expressed in ECs of numerous types of human carcinomas when compared with adjacent normal tissue, as well as xenograft tumors in mice including prostate, sarcoma, bladder, breast, lung tumors, and melanoma ( Figure 1A and 1B) . As a negative control, the primary antibody replaced by the isotype-matched irrelevant antibody showed no SCUBE2 immunostaining ( Figure I in the onlineonly Data Supplement). Therefore, endothelial SCUBE2 is highly expressed and may play an important role in tumor angiogenesis.
Impaired Tumor Growth in Scube2 EC-KO Mice
Given the highly selectively and elevated expression of SCUBE2 in tumor ECs and its essential role in adult neoangiogenesis, 28 we then investigated the role of SCUBE2 in pathological tumor angiogenesis and tumor growth. Tumor growth in control and EC-KO mice was measured after subcutaneous injection of mouse syngeneic melanoma (B16F10) or Lewis lung carcinoma (LLC) cells, both representing highly malignant tumors characterized by intense angiogenesis. Representative images in mice at day 16 after injection are shown in Figure 1C and 1D. Solid tumors, formed after injection of cells from either tumor cell line, grew slower and were smaller in EC-KO than control mice ( Figure 1E and 1F) . B16F10 tumors were 70% smaller in EC-KO than control mice (P<0.01), and LLC tumors were almost 40% smaller (P<0.01). These data suggest that endothelial deletion of SCUBE2 in mice may inhibit tumor growth.
Impaired Tumor Angiogenesis Leading to Increased Tumor Necrosis and Apoptosis in EC-KO Mice
To determine whether lack of endothelial SCUBE2 reduces tumor growth by disrupting tumor angiogenesis, we examined tumor vasculature in immunostained tissue sections. On immunostaining tumor sections with an antibody targeting the endothelial marker CD31, vascular density was lower in EC-KO than in control tumors ( Figure 1G and 1H). The EC-specific deletion of SCUBE2 in EC-KO mice was further confirmed in tumor sections ( Figure II in the online-only Data Supplement). Furthermore, the overall vascular density in tumor sections was quantified with anti-CD31-positive staining in vessels. Vascular density was significantly decreased in B16F10 and LLC tumors in EC-KO mice ( Figure 1G and 1H) . Together, these data suggest that endothelial SCUBE2 plays an essential role in promoting tumor angiogenesis and tumor growth. Importantly, vessel density in nontumorous adult skin was comparable between control and EC-KO animals (data not shown).
The angiogenesis defects observed in EC-KO mice implied that tumor cells might be deprived of nutrients and oxygen and therefore undergo apoptosis and necrosis. Consistent with this notion, hematoxylin and eosin staining revealed a central core of necrotic tissue in EC-KO tumors but a much smaller necrotic area in control tumors (Figure 2A and 2B). Furthermore, terminal deoxynucleotidyl transferase dUTP nick end labeling assay and Ki67 immunostaining showed greater apoptosis and markedly reduced proliferation of tumor cells in EC-KO than control tumors ( Figure 2C through 2F). We also found the tumor-suppressive effect in EC-KO mice in another tumor model: mouse testis Leydig tumor xenograft with MLTC-1 cells ( Figure III in the onlineonly Data Supplement). These results indicate that endothelial SCUBE2 is indispensable for angiogenesis to sustain the survival of tumor cells.
Production of a Functional Blocking mAb (SP.B1) Specific for SCUBE2
Because our genetic data clearly demonstrated that the membrane-associated SCUBE2 acting as a coreceptor for VEGFR2 plays an essential role in tumor angiogenesis, we evaluated whether inhibition of its surface expression by an mAb could be a potential pharmacological means for treating solid tumors. An mAb (clone SP.B1) specific for the spacer region, known to be important for SCUBE2 anchoring onto the cell surface 17 ( Figure IV in the online-only Data Supplement), was developed by conventional hybridoma technology (Figure 3 ). This mAb SP.B1 recognized only human and mouse SCUBE2 in ECs and did not cross-react with SCUBE1 or 3 ( Figure 3A) , which indicates lack of significant off-target effects. In addition, this anti-SCUBE2 SP.B1 could also bind SCUBE2 protein expressed on the cell surface of cultured human umbilical vein ECs as seen by flow cytometry ( Figure 3B ).
SP.B1 mAb Binding Induces SCUBE2 Internalization in ECs and Inhibits VEGF Signaling and Angiogenesis
Because the spacer region of SCUBE proteins is involved in the plasma membrane localization essential for its coreceptor function, 23 we then examined the effect of SP.B1 mAb on the cell surface SCUBE2 level and its VEGFR2 coreceptor function in ECs. SP.B1 but not control IgG dose dependently Because a synthetic oligonucleotide has been developed to bind a VEGF coreceptor, neuropilin-1, thereby resulting in receptor internalization and inhibition of angiogenesis, 33 we next examined whether SP.B1 can promote the internalization of SCUBE2, which would explain its reduced level on the cell surface after incubation with SP.B1. Using confocal microscopy, we traced SCUBE2 in ECs after incubation with SP.B1. When left untreated 28 or after incubation with control IgG ( Figure 4B , left), SCUBE2 was predominantly localized on the plasma membrane at the EC peripheral rim and barely detected inside cytoplasm, but after incubation with SP.B1, SCUBE2 was clearly detectable inside the cytoplasm, including the perinuclear region ( Figure 4B , right). Consistent with these data, the biotinylated EC surface SCUBE2 level was dose dependently decreased after incubation with SP.B1 ( Figure 4C and 4D) . We then investigated the localization of SCUBE2 in SP.B1-treated ECs by confocal microscopy, together with that of markers of endosome and lysosome pathway. SCUBE2 was clearly identified within vesicular cytoplasmic structures and colocalized with EEA1 (an early endosomal marker; Figure 4E ) and LAMP2 (a lysosomal marker; Figure 4F ). These observations demonstrated that SP.B1 promoted SCUBE2 internalization and trafficking to the endosomal-lysosomal compartment. Therefore, in the presence of SP.B1, cell surface SCUBE2 level was decreased, as measured by flow cytometry and quantitative surface biotinylation assay, and SCUBE2 moved from the cell surface rim to inside endosomes and lysosomes, as detected by confocal microscopy.
Given the proangiogenic activity of SCUBE2, we further assessed the potential functional significance of reduced surface SCUBE2 level by SP.B1. Incubation of SP.B1 mAb but not control IgG dose dependently reduced VEGF-induced downstream signaling, including VEGFR2 phosphorylation and p44/42 MAPK or AKT activation ( Figure 3F through 3I) , thereby suppressing VEGF-stimulated proliferation and tube formation of ECs ( Figure 3C through 3E) . Importantly, incubation of SP.B1 and bevacizumab simultaneously to human umbilical vein ECs inhibited VEGF signaling in an additive manner ( Figure VI in the online Data Supplement) Hence, SP.B1 mAb reduced EC surface level of the VEGFR2 coreceptor SCUBE2 and VEGF-induced signaling, proliferation, and angiogenesis in ECs.
Anti-SCUBE2 Combined With Anti-VEGF Had an Additive Effect in Reducing Tumor Growth
Tumor growth depends on angiogenesis, and blocking the VEGF pathway can inhibit tumor angiogenesis. 34 Our findings that SCUBE2 acts as a coreceptor for VEGFR2 prompted us to investigate whether SP.B1 and the anti-VEGF antibody bevacizumab had an additive effect on inhibiting tumor growth. We established a tumor model with the human pancreatic carcinoma cell line PANC-1, expressing a very low level or no amount of SCUBE2 ( Figure VIIA in the online-only Data Supplement). Therapeutic injection was started when pancreatic tumors reached 50 mm 3 . We first examined the doseresponse curve of anti-SCUBE2 SP.B1 and bevacizumab in the in vivo pancreatic tumor model ( Figure VIII in the onlineonly Data Supplement). The dose of SP.B1 and bevacizumab with the maximum antitumor efficacy was then used in combination to demonstrate their additive therapeutic effects. PANC-1 growth was markedly inhibited by SP.B1, bevacizumab, and combined treatment (SP.B1+bevacizumab) when compared with mouse or human IgG treatment ( Figure 5A and 5B). Interestingly, SP.B1+bevacizumab had greater inhibitory effect on tumor growth than SP.B1 or bevacizumab alone (72% versus 24% and 46%; Figure 5C ), so these 2 agents may act at least in part on different pathways critical for tumor angiogenesis. In addition, immunohistochemistry revealed significantly reduced microvascular density with SP.B1+bevacizumab combined ( Figure 5D and 5E) . Importantly, vessel numbers were 38% and 14% less with SP.B1+bevacizumab than SP.B1 or bevacizumab alone. SP.B1+bevacizumab-treated tumors showed significantly more necrosis than with singleagent therapy ( Figure IXA 
Combining SP.B1 With Gemcitabine or Docetaxel Chemotherapy Synergistically Inhibits PDAC Growth
Because almost all of the anti-VEGF bevacizumab approvals need to be combined with chemotherapy 8 and because bevacizumab is not effective for pancreatic cancer, 35 we tested whether combining anti-SCUBE2 SP.B1 with the cytotoxic chemotherapy agents gemcitabine or docetaxel that target different pathways of pancreatic ductal adenocarcinoma (PDAC) progression can offer a superior antitumor strategy. The effect of combining the antitumor agents SP.B1, gemcitabine, and docetaxel was examined in human PANC-1 PDAC xenografts. Compared with controls, single-agent therapy reduced tumor growth by 36% with SP.B1, 56% with gemcitabine, and 60% with docetaxel ( Figure 6A through 6D) . The dual combination 
Discussion
In this study, we show that the function of endothelial SCUBE2 is extended beyond adult neoangiogenesis 28 and further unravel its involvement in pathological tumor angiogenesis. We first observed that SCUBE2 expression is selective and highly enriched in tumor capillary ECs of many human and xenograft tumors. This finding agrees with our previous study showing that HIF-1α can bind onto a consensus HIF-binding motif in the upstream promoter of SCUBE2 and transactivate endothelial SCUBE2 expression in response to hypoxia, 28 present within the intratumoral microenvironment. 33 Furthermore, the genetic inactivation and pharmacological mAb blocking data we present here support that SCUBE2 critically participates in pathological tumor angiogenesis at least in functional cooperation with the VEGF/ VEGFR2 pathway.
Taking advantage of the surface-tethering nature of SCUBE2 as a peripheral membrane protein, we developed a functional blocking mAb for SCUBE2 to target the spacer region-critical for plasma membrane anchoring-that binds to SCUBE2 and triggers its internalization. Thus, SCUBE2 is sequestered away from the cell surface, which diminishes the binding of and signaling activity of VEGF in tumor ECs ( Figure 5F ). Because SCUBE2 can also physically interact with VEGF or VEGFR2 through its NH 2 -terminal EGF-like repeats or the COOH-terminal CUB domains, 28 mAbs specifically impeding these domains for their interaction with VEGF or VEGFR2 might serve as additional classes of anti-SCUBE2 neutralizing reagents for blocking tumor angiogenesis. This notion warrants further development and investigation.
We found that combined therapy with anti-SCUBE2 SP.B1 and the anti-VEGF antibody bevacizumab had an additive effect on tumor angiogenesis in xenograft human PDAC and colorectal carcinoma and LLC lung tumors. Such synergistic function between combined mAbs suggests that SCUBE2 and VEGFR2 might mediate some parallel and nonoverlapping signals. For instance, we and others have recently found that SCUBE2 can positively regulate SHH (sonic hedgehog) signaling. 17, 22, 36, 37 Because SHH has been implicated in neovascular formation, 39 whether this SCUBE2-promoted SHH signaling plays a role in tumor angiogenesis independent of VEGFR2 is of interest. Alternatively, junctional expression of endothelial SCUBE2 may functionally collaborate with VE-cadherin (a major adhesive protein of EC adherens junctions) essential in maintaining vascular stability, permeability, and angiogenesis 40 because epithelial SCUBE2 can associate with E-cadherin in maintaining the epithelial molecular phenotypes. 21 Current study demonstrated that combining anti-SCUBE2 SP.B1 with docetaxel or gemcitabine enhanced the antitumor effects on PDAC xenografts in mice when compared with single-agent treatment alone ( Figure 6 ; Figure XIII in the online-only Data Supplement). Our finding encourages a new therapeutic approach for PDAC by targeting SCUBE2 in combination with chemotherapeutics. Despite there was activity of bevacizumab in combination with gemcitabine or docetaxel in preclinical and early-phase clinical trials of PDAC, 40, 41 larger and phase 3 trials have failed to demonstrate a better survival outcome from adding bevacizumab to gemcitabine or docetaxel in patients with PDAC. 42 Previously, Bruns et al 44 demonstrated in vivo antitumor efficacy of an anti-VEGFR2 antibody DC-101 plus gemcitabine, and suggested that anti-VEGFR2 therapy in combination with gemcitabine may be a novel therapeutic approach for advanced pancreatic cancer. 43 Our new approach by targeting VEGFR2 coreceptor also effectively suppresses VEGF-induced responses and signal transduction ( Figure 3 ). On the basis of our current and past works on SCUBE2, SCUBE2 may serve as an ideal target because of not only its role in tumor angiogenesis but also its distinctive and diversified signaling roles in regulating SHH and perhaps VE-cadherin. 17, 21, 22, 44 Nevertheless, our data have provided a proof-of-concept model and warrant further investigation in future preclinical and clinical studies.
Global inactivation 22 and Scube2 EC-KO 28 in mice had no apparent adverse effects on vascular systems under normal physiological conditions, so the anti-SCUBE2 mAb might offer a relative nontoxic means to target tumor angiogenesis, particularly because SCUBE2 is selectively upregulated by hypoxia and highly expressed in tumor vasculatures. Nevertheless, further toxicological examinations are needed to evaluate the safety of administering the anti-SCUBE2 mAb together with the anti-VEGF antibody bevacizumab or cytotoxic chemotherapeutic agents such as docetaxel or gemcitabine in the clinic. In conclusion, our study revealed SCUBE2 as an essential VEGFR2 coreceptor during tumor angiogenesis, and targeting cell surface SCUBE2 expression represents a promising strategy for combined antiangiogenic treatment or cytotoxic chemotherapy.
